Abstract
Idiopathic pulmonary arterial hypertension (IPAH) is a rare but fatal disease diagnosed by right heart catheterisation and the exclusion of other forms of pulmonary arterial hypertension, producing a heterogeneous population with varied treatment response. Here we show unsupervised machine learning identification of three major patient subgroups that account for 92% of the cohort, each with unique whole blood transcriptomic and clinical feature signatures. These subgroups are associated with poor, moderate, and good prognosis. The poor prognosis subgroup is associated with upregulation of the ALAS2 and downregulation of several immunoglobulin genes, while the good prognosis subgroup is defined by upregulation of the bone morphogenetic protein signalling regulator NOG, and the C/C variant of HLA-DPA1/DPB1 (independently associated with survival). These findings independently validated provide evidence for the existence of 3 major subgroups (endophenotypes) within the IPAH classification, could improve risk stratification and provide molecular insights into the pathogenesis of IPAH.
Original language | English |
---|---|
Article number | 7104 |
Journal | Nature communications |
Volume | 12 |
Issue number | 1 |
DOIs | |
Publication status | Published - Dec 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Nature communications, Vol. 12, No. 1, 7104, 12.2021.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
AU - UK National PAH Cohort Study Consortium
AU - Kariotis, Sokratis
AU - Jammeh, Emmanuel
AU - Swietlik, Emilia M.
AU - Pickworth, Josephine A.
AU - Rhodes, Christopher J.
AU - Otero, Pablo
AU - Wharton, John
AU - Iremonger, James
AU - Dunning, Mark J.
AU - Pandya, Divya
AU - Mascarenhas, Thomas S.
AU - Errington, Niamh
AU - Thompson, A. A.Roger
AU - Romanoski, Casey E.
AU - Rischard, Franz
AU - Garcia, Joe G.N.
AU - Yuan, Jason X.J.
AU - An, Tae Hwi Schwantes
AU - Desai, Ankit A.
AU - Coghlan, Gerry
AU - Lordan, Jim
AU - Corris, Paul A.
AU - Howard, Luke S.
AU - Condliffe, Robin
AU - Kiely, David G.
AU - Church, Colin
AU - Pepke-Zaba, Joanna
AU - Toshner, Mark
AU - Wort, Stephen
AU - Gräf, Stefan
AU - Morrell, Nicholas W.
AU - Wilkins, Martin R.
AU - Lawrie, Allan
AU - Wang, Dennis
AU - Bleda, Marta
AU - Hadinnapola, Charaka
AU - Haimel, Matthias
AU - Auckland, Kate
AU - Tilly, Tobias
AU - Martin, Jennifer M.
AU - Yates, Katherine
AU - Treacy, Carmen M.
AU - Day, Margaret
AU - Greenhalgh, Alan
AU - Shipley, Debbie
AU - Peacock, Andrew J.
AU - Irvine, Val
AU - Kennedy, Fiona
AU - Bogaard, Harm J.
AU - Houweling, Arjan C.
N1 - Funding Information: The UK National Cohort of Idiopathic and Heritable PAH is supported by grants from the British Heart Foundation (SP/12/12/29836 & SP/18/10/33975) and the UK Medical Research Council (MR/K020919/1). Additional samples from the Sheffield Teaching Hospitals Observational Study of Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases were supported by British Heart Foundation (PG/11/116/29288). We gratefully acknowledge financial support from the UK Department of Health via the NIHR comprehensive Biomedical Research Centre award to Imperial College Healthcare NHS Trust, Cambridge Biomedical Research Centre, and Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust and the NIHR Imperial Clinical Research Facility. Sheffield NIHR Clinical Research Facility award to Sheffield Teaching Hospitals Foundation NHS Trust. S.K. is supported by a Donald Heath Ph.D. Studentship award; C.J.R. is supported by a British Heart Foundation Intermediate Basic Science Research fellowship (FS/15/59/ 31839). N.E. is supported by an EPSRC Centre for Doctoral Training; A.A.R.T. is supported by a British Heart Foundation Intermediate Clinical Research fellowship (FS/18/ 13/33281); N.W.M. is a British Heart Foundation Professor and NIHR Senior Investigator. A.L. is supported by a BHF Senior Basic Science Research fellowship (FS/18/52/ 33808). E.J. is supported by the Academy of Medical Sciences Springboard (ref: SBF004/ 1052). M.R.W. is in receipt of a British Heart Foundation Centre for Research Excellence award (RE/18/4/34215). M.J.D. and D.W. are supported by the NIHR Sheffield Biomedical Research Centre. We thank and thank all the patients and their families who contributed to this research, the UK Pulmonary Hypertension Association for their support, NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Publisher Copyright: © 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Idiopathic pulmonary arterial hypertension (IPAH) is a rare but fatal disease diagnosed by right heart catheterisation and the exclusion of other forms of pulmonary arterial hypertension, producing a heterogeneous population with varied treatment response. Here we show unsupervised machine learning identification of three major patient subgroups that account for 92% of the cohort, each with unique whole blood transcriptomic and clinical feature signatures. These subgroups are associated with poor, moderate, and good prognosis. The poor prognosis subgroup is associated with upregulation of the ALAS2 and downregulation of several immunoglobulin genes, while the good prognosis subgroup is defined by upregulation of the bone morphogenetic protein signalling regulator NOG, and the C/C variant of HLA-DPA1/DPB1 (independently associated with survival). These findings independently validated provide evidence for the existence of 3 major subgroups (endophenotypes) within the IPAH classification, could improve risk stratification and provide molecular insights into the pathogenesis of IPAH.
AB - Idiopathic pulmonary arterial hypertension (IPAH) is a rare but fatal disease diagnosed by right heart catheterisation and the exclusion of other forms of pulmonary arterial hypertension, producing a heterogeneous population with varied treatment response. Here we show unsupervised machine learning identification of three major patient subgroups that account for 92% of the cohort, each with unique whole blood transcriptomic and clinical feature signatures. These subgroups are associated with poor, moderate, and good prognosis. The poor prognosis subgroup is associated with upregulation of the ALAS2 and downregulation of several immunoglobulin genes, while the good prognosis subgroup is defined by upregulation of the bone morphogenetic protein signalling regulator NOG, and the C/C variant of HLA-DPA1/DPB1 (independently associated with survival). These findings independently validated provide evidence for the existence of 3 major subgroups (endophenotypes) within the IPAH classification, could improve risk stratification and provide molecular insights into the pathogenesis of IPAH.
UR - http://www.scopus.com/inward/record.url?scp=85120967466&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41467-021-27326-0
DO - https://doi.org/10.1038/s41467-021-27326-0
M3 - Article
C2 - 34876579
SN - 2041-1723
VL - 12
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 7104
ER -